MARKET

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.447
+0.117
+2.70%
Opening 11:17 04/23 EDT
OPEN
4.360
PREV CLOSE
4.330
HIGH
4.590
LOW
4.360
VOLUME
104.81K
TURNOVER
--
52 WEEK HIGH
8.09
52 WEEK LOW
1.700
MARKET CAP
139.77M
P/E (TTM)
-10.6817
1D
5D
1M
3M
1Y
5Y
Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates
Zacks.com · 1d ago
Anixa Biosciences (ANIX) Receives a Rating Update from a Top Analyst
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences (ANIX) today and set a price target of $11.00. The company's shares closed
SmarterAnalyst · 3d ago
Mid-Afternoon Market Update: Nasdaq Tumbles 150 Points; Knoll Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.41% to 34,060.60 while the NASDAQ fell 1.08% to 13,900.17. The S&P also fell, dropping 0.59% to 4,160.89.
Benzinga · 3d ago
Anixa's Stock Craters As FDA Slaps Clinical Hold On CAR-T Program
Benzinga · 3d ago
Mid-Day Market Update: Marlin Business Services Rises Following Acquisition News; Anixa Biosciences Shares Plummet
Midway through trading Monday, the Dow traded down 0.53% to 34,017.99. while the NASDAQ fell 0.94% to 13,920.74. The S&P also fell, dropping 0.54% to 4,162.85.
Benzinga · 3d ago
Chemomab Therapeutics, Obalon Therapeutics leads healthcare gainers; Haemonetics, 180 Life Sciences among major losers
Gainers: Chemomab Therapeutics (CMMB) +27%, Obalon Therapeutics (OBLN) +18%, Galectin Therapeutics (GALT) +13%, Sundial Growers (SNDL) +9%, Clover Health Investments (CLOV) +6%.Losers: Haemonetics (HAE) -31%, LifeMD (LFMD) -15%, 180 Life Sciences (ATNF) -1...
Seekingalpha · 4d ago
DJ Anixa Shares Fall After FDA Request Delays CAR-T Therapy Study >ANIX
Dow Jones · 4d ago
Mid-Morning Market Update: Markets Open Lower; Coca-Cola Tops Q1 Views
Following the market opening Monday, the Dow traded down 0.27% to 34,107.40 while the NASDAQ fell 0.72% to 13,950.87. The S&P also fell, dropping 0.32% to 4,171.87.
Benzinga · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIX. Analyze the recent business situations of Anixa Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIX stock price target is 9.50 with a high estimate of 11.00 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 31
Institutional Holdings: 1.83M
% Owned: 5.81%
Shares Outstanding: 31.43M
TypeInstitutionsShares
Increased
8
144.34K
New
5
65.15K
Decreased
6
94.13K
Sold Out
4
141.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.77%
Pharmaceuticals & Medical Research
+0.33%
Key Executives
Chairman/President/Chief Executive Officer/Director
Amit Kumar
Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Michael Catelani
Executive Vice President
Thomas Schlumpberger
Lead Director/Independent Director
Lewis Titterton
Independent Director
John Monanhan
Independent Director
Arnold Baskies
Independent Director
David Cavalier
Independent Director
Emily Gottschalk
Independent Director
John Monahan
No Data
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the body's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is curable. The Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients.

Webull offers kinds of Anixa Biosciences Inc stock information, including NASDAQ:ANIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIX stock methods without spending real money on the virtual paper trading platform.